Haemonetics Net Worth
Haemonetics Net Worth Breakdown | HAE |
Haemonetics Net Worth Analysis
Haemonetics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Haemonetics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Haemonetics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Haemonetics' net worth analysis. One common approach is to calculate Haemonetics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Haemonetics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Haemonetics' net worth. This approach calculates the present value of Haemonetics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Haemonetics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Haemonetics' net worth. This involves comparing Haemonetics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Haemonetics' net worth relative to its peers.
Enterprise Value |
|
To determine if Haemonetics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Haemonetics' net worth research are outlined below:
| Haemonetics generated a negative expected return over the last 90 days | |
| Haemonetics is unlikely to experience financial distress in the next 2 years | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Acquisition by Bryant Diane M of 2207 shares of Haemonetics subject to Rule 16b-3 |
Haemonetics Quarterly Good Will |
|
Haemonetics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Haemonetics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Haemonetics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 8th of February 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 9th of May 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of March 2023 Last Financial Announcement | View |
Haemonetics Target Price Consensus
Haemonetics target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Haemonetics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 10 | Strong Buy |
Most Haemonetics analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Haemonetics stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Haemonetics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationHaemonetics Target Price Projection
Haemonetics' current and average target prices are 64.80 and 110.80, respectively. The current price of Haemonetics is the price at which Haemonetics is currently trading. On the other hand, Haemonetics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Haemonetics Market Quote on 18th of March 2025
Target Price
Analyst Consensus On Haemonetics Target Price
Know Haemonetics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Haemonetics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Haemonetics backward and forwards among themselves. Haemonetics' institutional investor refers to the entity that pools money to purchase Haemonetics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Dimensional Fund Advisors, Inc. | 2024-12-31 | 992.2 K | Btim Corp | 2024-12-31 | 915.7 K | Schroder Investment Management Group | 2024-12-31 | 894.5 K | Sg Capital Management, Llc | 2024-12-31 | 878.8 K | Westfield Capital Management Company, L.p. | 2024-12-31 | 805.9 K | Allspring Global Investments Holdings, Llc | 2024-12-31 | 801 K | Fmr Inc | 2024-12-31 | 796.7 K | Fisher Asset Management, Llc | 2024-12-31 | 711.8 K | Goldman Sachs Group Inc | 2024-12-31 | 695.3 K | Blackrock Inc | 2024-12-31 | 6.2 M | Vanguard Group Inc | 2024-12-31 | 5.2 M |
Follow Haemonetics' market capitalization trends
The company currently falls under 'Mid-Cap' category with a total capitalization of 3.29 B.Market Cap |
|
Project Haemonetics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.05 | 0.08 | |
| Return On Capital Employed | 0.07 | 0.06 | |
| Return On Assets | 0.04 | 0.07 | |
| Return On Equity | 0.06 | 0.10 |
When accessing Haemonetics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Haemonetics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Haemonetics' profitability and make more informed investment decisions.
Please note, the presentation of Haemonetics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Haemonetics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Haemonetics' management manipulating its earnings.
Evaluate Haemonetics' management efficiency
Haemonetics has Return on Asset of 0.0633 % which means that on every $100 spent on assets, it made $0.0633 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1406 %, implying that it generated $0.1406 on every 100 dollars invested. Haemonetics' management efficiency ratios could be used to measure how well Haemonetics manages its routine affairs as well as how well it operates its assets and liabilities. At present, Haemonetics' Return On Assets are projected to increase slightly based on the last few years of reporting. The current year's Return On Equity is expected to grow to 0.10, whereas Return On Capital Employed is forecasted to decline to 0.06. At present, Haemonetics' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 99.2 M, whereas Other Assets are forecasted to decline to 1.09.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 14.26 | 7.57 | |
| Tangible Book Value Per Share | 7.29 | 5.03 | |
| Enterprise Value Over EBITDA | 25.70 | 26.99 | |
| Price Book Value Ratio | 5.13 | 2.79 | |
| Enterprise Value Multiple | 25.70 | 26.99 | |
| Price Fair Value | 5.13 | 2.79 | |
| Enterprise Value | 1.4 B | 1.5 B |
Evaluating the management effectiveness of Haemonetics allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The Haemonetics Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Enterprise Value Revenue 3.0546 | Revenue | Quarterly Revenue Growth 0.037 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Haemonetics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Haemonetics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Haemonetics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Haemonetics Corporate Filings
8K | 3rd of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 14th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
13A | 12th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
F4 | 5th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Haemonetics Earnings Estimation Breakdown
The calculation of Haemonetics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Haemonetics is estimated to be 1.13635 with the future projection ranging from a low of 1.125 to a high of 1.155. Please be aware that this consensus of annual earnings estimates for Haemonetics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
1.12 Lowest | Expected EPS | 1.16 Highest |
Haemonetics Earnings Projection Consensus
Suppose the current estimates of Haemonetics' value are higher than the current market price of the Haemonetics stock. In this case, investors may conclude that Haemonetics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Haemonetics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2025 | Current EPS (TTM) | |
| 10 | 90.48% | 1.19 | 1.13635 | 2.54 |
Haemonetics Earnings History
Earnings estimate consensus by Haemonetics analysts from Wall Street is used by the market to judge Haemonetics' stock performance. Investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we recommend analyzing not only Haemonetics' upcoming profit reports and earnings-per-share forecasts but also comparing them to our different valuation methods.Haemonetics Quarterly Gross Profit |
|
Haemonetics Earnings per Share Projection vs Actual
Actual Earning per Share of Haemonetics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Haemonetics predict the company's earnings will be in the future. The higher the earnings per share of Haemonetics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Haemonetics Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Haemonetics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Haemonetics should always be considered in relation to other companies to make a more educated investment decision.Haemonetics Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Haemonetics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-02-06 | 2024-12-31 | 1.1706 | 1.19 | 0.0194 | 1 | ||
2024-11-07 | 2024-09-30 | 1.07 | 1.12 | 0.05 | 4 | ||
2024-08-08 | 2024-06-30 | 1.01 | 1.02 | 0.01 | 0 | ||
2024-05-09 | 2024-03-31 | 0.89 | 0.9 | 0.01 | 1 | ||
2024-02-08 | 2023-12-31 | 0.94 | 1.04 | 0.1 | 10 | ||
2023-11-02 | 2023-09-30 | 0.89 | 0.99 | 0.1 | 11 | ||
2023-08-08 | 2023-06-30 | 0.73 | 1.05 | 0.32 | 43 | ||
2023-05-11 | 2023-03-31 | 0.7 | 0.77 | 0.07 | 10 | ||
2023-02-07 | 2022-12-31 | 0.8 | 0.85 | 0.05 | 6 | ||
2022-11-07 | 2022-09-30 | 0.67 | 0.83 | 0.16 | 23 | ||
2022-08-10 | 2022-06-30 | 0.51 | 0.58 | 0.07 | 13 | ||
2022-05-10 | 2022-03-31 | 0.6 | 0.65 | 0.05 | 8 | ||
2022-02-08 | 2021-12-31 | 0.73 | 0.84 | 0.11 | 15 | ||
2021-11-09 | 2021-09-30 | 0.61 | 0.6 | -0.01 | 1 | ||
2021-08-11 | 2021-06-30 | 0.45 | 0.5 | 0.05 | 11 | ||
2021-05-13 | 2021-03-31 | 0.67 | 0.46 | -0.21 | 31 | ||
2021-02-02 | 2020-12-31 | 0.65 | 0.81 | 0.16 | 24 | ||
2020-11-04 | 2020-09-30 | 0.51 | 0.62 | 0.11 | 21 | ||
2020-08-04 | 2020-06-30 | 0.41 | 0.46 | 0.05 | 12 | ||
2020-05-05 | 2020-03-31 | 0.73 | 0.69 | -0.04 | 5 | ||
2020-02-04 | 2019-12-31 | 0.76 | 0.94 | 0.18 | 23 | ||
2019-11-01 | 2019-09-30 | 0.69 | 0.87 | 0.18 | 26 | ||
2019-08-06 | 2019-06-30 | 0.63 | 0.81 | 0.18 | 28 | ||
2019-05-07 | 2019-03-31 | 0.55 | 0.61 | 0.06 | 10 | ||
2019-02-05 | 2018-12-31 | 0.59 | 0.63 | 0.04 | 6 | ||
2018-11-06 | 2018-09-30 | 0.54 | 0.56 | 0.02 | 3 | ||
2018-08-07 | 2018-06-30 | 0.42 | 0.59 | 0.17 | 40 | ||
2018-05-08 | 2018-03-31 | 0.42 | 0.43 | 0.01 | 2 | ||
2018-02-06 | 2017-12-31 | 0.44 | 0.62 | 0.18 | 40 | ||
2017-11-07 | 2017-09-30 | 0.41 | 0.48 | 0.07 | 17 | ||
2017-08-07 | 2017-06-30 | 0.31 | 0.33 | 0.02 | 6 | ||
2017-05-08 | 2017-03-31 | 0.38 | 0.39 | 0.01 | 2 | ||
2017-02-06 | 2016-12-31 | 0.41 | 0.43 | 0.02 | 4 | ||
2016-11-07 | 2016-09-30 | 0.35 | 0.46 | 0.11 | 31 | ||
2016-08-01 | 2016-06-30 | 0.28 | 0.25 | -0.03 | 10 | ||
2016-05-02 | 2016-03-31 | 0.46 | 0.37 | -0.09 | 19 | ||
2016-02-01 | 2015-12-31 | 0.46 | 0.48 | 0.02 | 4 | ||
2015-11-04 | 2015-09-30 | 0.39 | 0.44 | 0.05 | 12 | ||
2015-07-27 | 2015-06-30 | 0.32 | 0.35 | 0.03 | 9 | ||
2015-04-27 | 2015-03-31 | 0.52 | 0.47 | -0.05 | 9 | ||
2015-01-29 | 2014-12-31 | 0.51 | 0.53 | 0.02 | 3 | ||
2014-11-03 | 2014-09-30 | 0.46 | 0.47 | 0.01 | 2 | ||
2014-07-30 | 2014-06-30 | 0.36 | 0.38 | 0.02 | 5 | ||
2014-04-28 | 2014-03-31 | 0.58 | 0.46 | -0.12 | 20 | ||
2014-01-27 | 2013-12-31 | 0.6 | 0.61 | 0.01 | 1 | ||
2013-10-28 | 2013-09-30 | 0.58 | 0.66 | 0.08 | 13 | ||
2013-07-29 | 2013-06-30 | 0.47 | 0.46 | -0.01 | 2 | ||
2013-05-01 | 2013-03-31 | 0.46 | 0.48 | 0.02 | 4 | ||
2013-01-30 | 2012-12-31 | 0.47 | 0.5 | 0.03 | 6 | ||
2012-10-29 | 2012-09-30 | 0.38 | 0.45 | 0.07 | 18 | ||
2012-08-01 | 2012-06-30 | 0.36 | 0.28 | -0.08 | 22 | ||
2012-04-30 | 2012-03-31 | 0.42 | 0.4 | -0.02 | 4 | ||
2012-01-30 | 2011-12-31 | 0.4 | 0.43 | 0.03 | 7 | ||
2011-10-31 | 2011-09-30 | 0.38 | 0.36 | -0.02 | 5 | ||
2011-08-01 | 2011-06-30 | 0.39 | 0.33 | -0.06 | 15 | ||
2011-05-02 | 2011-03-31 | 0.41 | 0.43 | 0.02 | 4 | ||
2011-01-31 | 2010-12-31 | 0.41 | 0.45 | 0.04 | 9 | ||
2010-11-01 | 2010-09-30 | 0.38 | 0.4 | 0.02 | 5 | ||
2010-08-02 | 2010-06-30 | 0.36 | 0.37 | 0.01 | 2 | ||
2010-05-04 | 2010-03-31 | 0.38 | 0.38 | 0.0 | 0 | ||
2010-02-01 | 2009-12-31 | 0.36 | 0.36 | 0.0 | 0 | ||
2009-11-02 | 2009-09-30 | 0.32 | 0.35 | 0.03 | 9 | ||
2009-08-03 | 2009-06-30 | 0.33 | 0.35 | 0.02 | 6 | ||
2009-05-04 | 2009-03-31 | 0.31 | 0.33 | 0.02 | 6 | ||
2009-02-02 | 2008-12-31 | 0.3 | 0.32 | 0.02 | 6 | ||
2008-10-27 | 2008-09-30 | 0.26 | 0.29 | 0.03 | 11 | ||
2008-08-01 | 2008-06-30 | 0.27 | 0.3 | 0.03 | 11 | ||
2008-05-01 | 2008-03-31 | 0.29 | 0.29 | 0.0 | 0 | ||
2008-01-31 | 2007-12-31 | 0.27 | 0.28 | 0.01 | 3 | ||
2007-11-01 | 2007-09-30 | 0.23 | 0.23 | 0.0 | 0 | ||
2007-08-02 | 2007-06-30 | 0.25 | 0.25 | 0.0 | 0 | ||
2007-05-02 | 2007-03-31 | 0.29 | 0.33 | 0.04 | 13 | ||
2007-01-31 | 2006-12-31 | 0.25 | 0.28 | 0.03 | 12 | ||
2006-10-31 | 2006-09-30 | 0.24 | 0.23 | -0.01 | 4 | ||
2006-07-27 | 2006-06-30 | 0.28 | 0.26 | -0.02 | 7 | ||
2006-05-03 | 2006-03-31 | 0.28 | 0.31 | 0.03 | 10 | ||
2006-01-31 | 2005-12-31 | 0.23 | 0.25 | 0.02 | 8 | ||
2005-10-27 | 2005-09-30 | 0.19 | 0.2 | 0.01 | 5 | ||
2005-07-28 | 2005-06-30 | 0.19 | 0.24 | 0.05 | 26 | ||
2005-05-05 | 2005-03-31 | 0.18 | 0.19 | 0.01 | 5 | ||
2005-01-31 | 2004-12-31 | 0.18 | 0.21 | 0.03 | 16 | ||
2004-11-01 | 2004-09-30 | 0.17 | 0.17 | 0.0 | 0 | ||
2004-07-29 | 2004-06-30 | 0.17 | 0.19 | 0.02 | 11 | ||
2004-05-03 | 2004-03-31 | 0.17 | 0.19 | 0.02 | 11 | ||
2004-01-22 | 2003-12-31 | 0.17 | 0.19 | 0.02 | 11 | ||
2003-10-23 | 2003-09-30 | 0.13 | 0.15 | 0.02 | 15 | ||
2003-07-24 | 2003-06-30 | 0.1 | 0.11 | 0.01 | 10 | ||
2003-04-24 | 2003-03-31 | 0.12 | 0.09 | -0.03 | 25 | ||
2003-01-23 | 2002-12-31 | 0.18 | 0.21 | 0.03 | 16 | ||
2002-10-24 | 2002-09-30 | 0.13 | 0.14 | 0.01 | 7 | ||
2002-07-25 | 2002-06-30 | 0.13 | 0.13 | 0.0 | 0 | ||
2002-05-02 | 2002-03-31 | 0.15 | 0.14 | -0.01 | 6 | ||
2002-01-24 | 2001-12-31 | 0.17 | 0.18 | 0.01 | 5 | ||
2001-10-25 | 2001-09-30 | 0.15 | 0.19 | 0.04 | 26 | ||
2001-07-26 | 2001-06-30 | 0.15 | 0.19 | 0.04 | 26 | ||
2001-05-03 | 2001-03-31 | 0.14 | 0.14 | 0.0 | 0 | ||
2001-01-25 | 2000-12-31 | 0.15 | 0.17 | 0.02 | 13 | ||
2000-10-26 | 2000-09-30 | 0.13 | 0.13 | 0.0 | 0 | ||
2000-07-27 | 2000-06-30 | 0.13 | 0.13 | 0.0 | 0 | ||
2000-05-04 | 2000-03-31 | 0.14 | 0.14 | 0.0 | 0 | ||
2000-01-27 | 1999-12-31 | 0.13 | 0.13 | 0.0 | 0 | ||
1999-10-28 | 1999-09-30 | 0.1 | 0.11 | 0.01 | 10 | ||
1999-07-29 | 1999-06-30 | 0.09 | 0.11 | 0.02 | 22 | ||
1999-05-06 | 1999-03-31 | 0.09 | 0.12 | 0.03 | 33 | ||
1999-01-29 | 1998-12-31 | 0.1 | 0.09 | -0.01 | 10 | ||
1998-10-26 | 1998-09-30 | 0.08 | 0.1 | 0.02 | 25 | ||
1998-07-27 | 1998-06-30 | 0.08 | 0.1 | 0.02 | 25 | ||
1998-05-04 | 1998-03-31 | 0.11 | -0.06 | -0.17 | 154 | ||
1998-01-27 | 1997-12-31 | 0.11 | 0.09 | -0.02 | 18 | ||
1997-10-16 | 1997-09-30 | 0.11 | 0.08 | -0.03 | 27 | ||
1997-04-15 | 1997-03-31 | 0.13 | 0.14 | 0.01 | 7 | ||
1997-01-14 | 1996-12-31 | 0.13 | 0.13 | 0.0 | 0 | ||
1996-10-11 | 1996-09-30 | 0.17 | 0.16 | -0.01 | 5 | ||
1996-07-15 | 1996-06-30 | 0.16 | 0.17 | 0.01 | 6 | ||
1996-04-18 | 1996-03-31 | 0.17 | 0.17 | 0.0 | 0 | ||
1996-01-15 | 1995-12-31 | 0.16 | 0.16 | 0.0 | 0 | ||
1995-10-15 | 1995-09-30 | 0.16 | 0.17 | 0.01 | 6 | ||
1995-07-16 | 1995-06-30 | 0.16 | 0.16 | 0.0 | 0 |
Haemonetics Corporate Directors
| Robert Abernathy | Independent Director | Profile | |
| Claire Pomeroy | Independent Director | Profile | |
| Catherine Burzik | Independent Director | Profile | |
| Mark Kroll | Independent Director | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Haemonetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Haemonetics. If investors know Haemonetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Haemonetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.213 | Earnings Share 2.54 | Revenue Per Share | Quarterly Revenue Growth 0.037 | Return On Assets |
The market value of Haemonetics is measured differently than its book value, which is the value of Haemonetics that is recorded on the company's balance sheet. Investors also form their own opinion of Haemonetics' value that differs from its market value or its book value, called intrinsic value, which is Haemonetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Haemonetics' market value can be influenced by many factors that don't directly affect Haemonetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Haemonetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Haemonetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Haemonetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.